Geron Corporation - Asset Resilience Ratio
Geron Corporation (GERN) has an Asset Resilience Ratio of 53.30% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read GERN liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Geron Corporation's Asset Resilience Ratio has changed over time. See Geron Corporation shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Geron Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Geron Corporation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $302.42 Million | 53.3% |
| Total Liquid Assets | $302.42 Million | 53.30% |
Asset Resilience Insights
- Very High Liquidity: Geron Corporation maintains exceptional liquid asset reserves at 53.30% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Geron Corporation Industry Peers by Asset Resilience Ratio
Compare Geron Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Geron Corporation (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Geron Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 55.16% | $327.55 Million | $593.78 Million | -11.75pp |
| 2023-12-31 | 66.91% | $263.68 Million | $394.08 Million | +6.09pp |
| 2022-12-31 | 60.82% | $115.90 Million | $190.57 Million | -5.04pp |
| 2021-12-31 | 65.85% | $148.85 Million | $226.03 Million | -2.98pp |
| 2020-12-31 | 68.83% | $186.35 Million | $270.73 Million | -7.10pp |
| 2019-12-31 | 75.93% | $125.68 Million | $165.52 Million | -6.49pp |
| 2018-12-31 | 82.42% | $152.71 Million | $185.28 Million | +11.40pp |
| 2017-12-31 | 71.03% | $78.35 Million | $110.31 Million | -7.31pp |
| 2016-12-31 | 78.34% | $102.03 Million | $130.25 Million | +16.14pp |
| 2015-12-31 | 62.20% | $92.52 Million | $148.76 Million | -0.78pp |
| 2014-12-31 | 62.98% | $108.64 Million | $172.51 Million | -14.58pp |
| 2013-12-31 | 77.56% | $52.23 Million | $67.34 Million | +3.94pp |
| 2012-12-31 | 73.62% | $73.47 Million | $99.80 Million | +7.88pp |
| 2011-12-31 | 65.74% | $105.21 Million | $160.05 Million | +5.54pp |
| 2010-12-31 | 60.19% | $140.60 Million | $233.58 Million | +17.50pp |
| 2009-12-31 | 42.69% | $77.01 Million | $180.38 Million | +12.34pp |
| 2008-12-31 | 30.36% | $53.49 Million | $176.22 Million | +2.95pp |
| 2007-12-31 | 27.40% | $59.98 Million | $218.90 Million | -7.68pp |
| 2006-12-31 | 35.08% | $77.45 Million | $220.80 Million | -11.55pp |
| 2005-12-31 | 46.63% | $93.84 Million | $201.24 Million | -36.87pp |
| 2004-12-31 | 83.50% | $110.12 Million | $131.87 Million | +1.86pp |
| 2003-12-31 | 81.64% | $96.43 Million | $118.11 Million | +11.78pp |
| 2002-12-31 | 69.86% | $42.38 Million | $60.67 Million | +17.72pp |
| 2001-12-31 | 52.13% | $50.17 Million | $96.23 Million | +49.47pp |
| 2000-12-31 | 2.67% | $3.04 Million | $114.03 Million | -- |
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.